Fewer than a tenth of patients eligible to benefit from obesity jabs such as Wegovy are able to get them, states the World Health Organization as it publishes its first guidance on the medications.
Considering over a billion individuals worldwide currently obese, it is calling for increased and just availability to GLP-1 medication.
Based on estimates, in excess of 2,000,000,000 are projected to be living with obesity by 2030 if no action is taken.
"The new guidance affirms that obesity is a long-term condition that can be addressed with thorough and ongoing support," said its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are key obstacles to broad access to the treatments that can help people shift significant weight, notes the agency.
Skinny Jab Supply Crisis
Even in the current most optimistic outlook, the production of these medications might only reach around 100 million people – less than 10% of eligible patients, as stated by the WHO.
The recommendation calls on governments and firms to widen access, by approaches including voluntary licensing.
The intellectual property rights on a key compound – the core ingredient of a leading brand – is set to lapse in a number of countries in 2026.
The Way Weight-Loss Injections Function
The injections replicate a body's own hormone to slow digestion, curb appetite and increase feelings of fullness so users reduce food intake.
People commonly begin shedding pounds within a few weeks of commencing the regular doses.
Research points to patients may see weight return within a year of stopping the treatment, because their typical food cravings resume.
To be overweight or obese increases your chance for contracting diseases, like type 2 diabetes, heart disease, brain attack, and some cancers.
Excess weight concerns people in all nations and was associated with 3.7 million deaths worldwide in 2024, per the health agency.
